BioCryst Pharmaceuticals (BCRX) Earnings Expected to Grow: Should You Buy?
BioCryst Pharmaceuticals (BCRX) is expected to report a year-over-year increase in earnings and higher revenues for the quarter ended December 2025. The company has a Zacks Earnings ESP of +23.08% and a Zacks Rank #3 (Hold), suggesting a high probability of beating consensus EPS estimates. Investors should also consider other factors beyond the earnings beat or miss.
Evercore ISI resumes BioCryst Pharma stock coverage with outperform rating
Evercore ISI has resumed coverage of BioCryst Pharma with an outperform rating and a $17.00 price target following the acquisition of ATXS. The firm sees 150% upside from current levels, aligning with a "Strong Buy" consensus, though acknowledging near-term uncertainty due to upcoming prophylaxis data. BioCryst recently reported strong full-year 2025 revenue from its ORLADEYO treatment and impressive Q4 sales.
Evercore ISI resumes BioCryst Pharma stock coverage with outperform rating
Evercore ISI has resumed coverage of BioCryst Pharma (NASDAQ:BCRX) with an "outperform" rating and a price target of $17.00, representing a 150% upside. This decision follows BioCryst's acquisition of ATXS and aligns with a "Strong Buy" consensus from other analysts. While near-term returns are uncertain due to upcoming prophylaxis data in Q3 2026, the firm is evaluating the stock over a one-to-two-year timeframe and has added it to its Core SMID list.
BioCryst Pharmaceuticals (NASDAQ:BCRX) Coverage Initiated at Evercore
Evercore has initiated coverage on BioCryst Pharmaceuticals (NASDAQ:BCRX) with an "outperform" rating and a $17.00 price target, suggesting a significant upside. The company's stock currently holds a "Moderate Buy" consensus rating from analysts, with an average price target of $19.64. Despite some insider selling, institutional investors hold a substantial portion of the shares, with Baker Bros. recently adding a new position.
(BCRX) Price Dynamics and Execution-Aware Positioning
This article analyzes Biocryst Pharmaceuticals Inc. (BCRX) price dynamics, highlighting a shift in near-term sentiment while broader alignment remains weak. It presents AI-generated trading strategies for different risk profiles, including long, breakout, and short positions, along with multi-timeframe signal analysis. The report also notes an exceptional risk-reward short setup with significant downside potential.
BioCryst to Present at Upcoming Investor Conference
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced its plan to present at the T.D. Cowen 46th Annual Health Care Conference. The presentation is scheduled for Tuesday, March 3, 2026, at 9:10 a.m. ET in Boston. This conference provides a platform for the company to share updates.
BioCryst to Present at Upcoming Investor Conference
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced it will present at the T.D. Cowen 46th Annual Health Care Conference in Boston on March 3, 2026, at 9:10 a.m. ET. A live audio webcast will be available on the Investors & Media section of BioCryst's website. BioCryst focuses on developing and commercializing medicines for rare diseases like hereditary angioedema (HAE).
BioCryst lines up March 3 slot at T.D. Cowen health care conference
BioCryst Pharmaceuticals (Nasdaq: BCRX) announced it will present at the T.D. Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026, at 9:10 a.m. ET. A live audio webcast and replay of the presentation will be available on the Investors & Media section of BioCryst's website. The company is focused on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases.
Hereditary Angioedema Clinical Trial Pipeline Expands as 20+
The Hereditary Angioedema (HAE) clinical trial pipeline is expanding significantly, with over 20 companies developing more than 30 therapeutic drugs. DelveInsight's report highlights key advancements, including BioCryst's acquisition of Astria Therapeutics and Intellia's Phase 3 HAELO trial for NTLA-2002. Promising emerging therapies like KalVista Pharmaceuticals' KVD900 and Pharvaris' PHA121, both oral plasma kallikrein inhibitors, are progressing through clinical stages, aiming to offer new and convenient treatment options for HAE patients.
Biocryst slated to present new Orladeyo, navenibart data at AAAAI
Biocryst Pharmaceuticals will present new clinical trial and real-world data for its hereditary angioedema (HAE) treatments, Orladeyo and navenibart, at the upcoming AAAAI annual meeting. The presentation will include interim results from the Phase 3 APeX-P trial for Orladeyo in pediatric patients aged 2 to under 12, showcasing reductions in attack rates and HAE symptoms. Additionally, new clinical trial results for the investigational therapy navenibart will be presented, highlighting its long-term effectiveness in preventing HAE attacks.
BioCryst Pharmaceuticals (BCRX) Is Up 9.0% After Navenibart ALPHA-SOLAR Data And Astria Deal News – Has The Bull Case Changed?
BioCryst Pharmaceuticals' stock rose 9.0% following its acquisition of Astria Therapeutics for US$700 million and the presentation of positive interim ALPHA-SOLAR trial data for navenibart, particularly in hereditary angioedema (HAE) treatment. This acquisition and positive trial data suggest a potential strategic shift towards long-acting preventive treatment options and diversify its HAE portfolio beyond ORLADEYO. However, the increased debt from the M&A raises concerns about balance sheet flexibility if future trials do not meet expectations.
A Look At BioCryst Pharmaceuticals (BCRX) Valuation After New Hereditary Angioedema Data And Conference Spotlight
BioCryst Pharmaceuticals (BCRX) is gaining attention due to new hereditary angioedema data, including positive interim ALPHA-SOLAR data for navenibart and real-world results for ORLADEYO. Despite recent short-term share price increases, the company has seen longer-term declines and remains unprofitable, yet it is significantly undervalued by one analyst's fair value estimate of $20.50 compared to its current price of $6.84. This valuation hinges on sustained revenue growth for ORLADEYO and successful commercialization of its early-stage pipeline, requiring strong performance against competitors and improved profit margins.
A Look At BioCryst Pharmaceuticals (BCRX) Valuation After New Hereditary Angioedema Data And Conference Spotlight
BioCryst Pharmaceuticals is gaining attention after announcing new hereditary angioedema data, including positive interim ALPHA-SOLAR results for navenibart and real-world results for ORLADEYO. Despite recent short-term share price gains, longer-term returns have been weak, and the company remains unprofitable. The article suggests BioCryst is significantly undervalued based on analyst predictions for its rare disease pipeline, contingent on ORLADEYO's continued effectiveness against competitors and successful commercialization of early-stage drugs.
BioCryst Pharmaceuticals to Present Nine Abstracts on Hereditary Angioedema at 2026 AAAAI Annual Meeting
BioCryst Pharmaceuticals will present nine abstracts on its hereditary angioedema (HAE) portfolio at the 2026 AAAAI Annual Meeting in Philadelphia. The presentations will include clinical trial data for ORLADEYO® (berotralstat), a targeted oral therapy for HAE, and new findings on navenibart, a monoclonal antibody for long-term HAE attack prevention, including a late-breaking abstract. The company aims to highlight its advancements in expanding HAE treatment options based on patient needs and clinical evidence.
Shots every 3–6 months suppress HAE attacks in BioCryst trial data
BioCryst Pharmaceuticals (NASDAQ: BCRX) announced it will present nine abstracts on Hereditary Angioedema (HAE) at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting. Key data includes interim results from the APeX-P trial for ORLADEYO in pediatric patients and a late-breaking ALPHA-SOLAR interim study showing sustained HAE attack suppression with navenibart administered every 3 or 6 months. These presentations highlight BioCryst's strategy to expand and diversify its HAE portfolio with both oral and long-acting injectable treatment options.
BioCryst to Present New HAE Data from ORLADEYO®
BioCryst Pharmaceuticals will present nine abstracts from its hereditary angioedema (HAE) portfolio at the 2026 AAAAI Annual Meeting. The data includes new clinical trial and real-world outcomes for ORLADEYO® (berotralstat), specifically for patients aged 2 and older, and positive interim results for navenibart, a long-acting monoclonal antibody for HAE prophylaxis. This presentation highlights BioCryst's commitment to expanding and diversifying its HAE treatment options.
BioCryst Uses Equity Grants To Support Rare Disease Pipeline And Talent
BioCryst Pharmaceuticals has granted inducement stock options and restricted stock units to 24 new employees, aiming to strengthen its talent pool for rare disease and infectious condition treatments. These equity awards are part of a strategy to attract and retain specialized expertise, aligning employee interests with the company's long-term performance and pipeline goals. The grants will help BioCryst manage long development cycles and product concentration on ORLADEYO while advancing new indications.
BioCryst to Report Fourth Quarter 2025 Financial Results on February 26
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced it will report its fourth quarter 2025 financial results on Thursday, February 26, 2026. The company will host a conference call and webcast at 8:30 a.m. ET to discuss the results and provide a corporate update. BioCryst is a global biotechnology company focused on developing and commercializing medicines for rare diseases like hereditary angioedema (HAE).
BioCryst Uses Equity Grants To Support Rare Disease Pipeline And Talent
BioCryst Pharmaceuticals granted inducement stock options and restricted stock units to 24 new hires as part of its talent acquisition and retention program. This move aims to secure specialized expertise needed for its rare disease and infectious conditions pipeline, especially given the company's reliance on ORLADEYO. The equity awards align employee interests with long-term business goals, encouraging talent retention through key developmental and commercial milestones.
Jim Cramer on BioCryst Pharmaceuticals: “Just Stay Away From That”
Jim Cramer advised against investing in BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), calling it a "very bad stock for a very long time." The company, which specializes in rare disease treatments, recently acquired Astria Therapeutics for $700 million, adding a Phase 3 therapy for hereditary angioedema to its portfolio. Despite this, Cramer remains bearish, suggesting investors look into more promising AI stocks instead.
Jim Cramer on BioCryst Pharmaceuticals: "Just Stay Away From That"
Jim Cramer advised against investing in BioCryst Pharmaceuticals (BCRX), citing its history as a "very bad stock." The company, which specializes in treatments for rare diseases, recently acquired Astria Therapeutics for $700 million, adding a Phase 3 therapy for hereditary angioedema to its portfolio. Despite this, Cramer believes the stock will not improve, while the article also suggests other AI stocks might offer better potential.
(BCRX) as a Liquidity Pulse for Institutional Tactics
This article analyzes BioCryst Pharmaceuticals Inc. (BCRX), highlighting weak sentiment across all time horizons and supporting a short bias for institutional tactics. It outlines specific trading strategies (Position Trading, Momentum Breakout, and Risk Hedging) with detailed entry, target, and stop-loss levels, alongside multi-timeframe signal analysis indicating support and resistance levels. The analysis suggests an exceptional 64.0:1 risk-reward setup, targeting a significant gain with minimal risk.
Jim Cramer Commented on These 14 Stocks
Jim Cramer has commented on 14 stocks, offering his perspective on each. This article specifically highlights his negative stance on BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), advising investors to avoid the stock due to its long history of poor performance, despite the company's recent acquisition of Astria Therapeutics and its rare disease pipeline.
BioCryst (BCRX) Grants Stock Options and RSUs to New Employees
BioCryst Pharmaceuticals (BCRX) has granted stock options and restricted stock units (RSUs) to 24 new employees, totaling 619,700 shares as an incentive. While the company shows strong revenue growth, its financial health indicators, such as an Altman Z-Score of -1.95 and a low interest coverage ratio, raise concerns about potential bankruptcy risk. Despite these risks, the stock's valuation metrics suggest it is trading near historical lows, and analyst sentiment is cautiously optimistic with a "moderate buy" recommendation.
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BioCryst Pharmaceuticals, Inc. announced that its compensation committee granted stock options and restricted stock units (RSUs) to 24 newly-hired employees. These grants, totaling 251,150 shares in stock options and 368,550 shares in RSUs, were made as inducements for employment and are in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $6.63 per share and both options and RSUs vest over four years, subject to continued service.
BioCryst to Report Fourth Quarter 2025 Financial Results on February 26
BioCryst Pharmaceuticals, Inc. announced it will report its fourth-quarter 2025 financial results on Thursday, February 26, 2026. The company will host a conference call and webcast at 8:30 a.m. ET to discuss these results and provide a corporate update. BioCryst is a biotechnology company focused on developing and commercializing medicines for rare diseases like hereditary angioedema.
Will BioCryst's ORLADEYO Hit The $1 Billion Sales Mark?
BioCryst Pharmaceuticals' shares are down over 40% from their 52-week high, with the company focusing on its primary product, ORLADEYO, for hereditary angioedema. ORLADEYO's net sales have consistently grown, and BioCryst aims to reach $1 billion in annual sales by 2029. The company has also expanded its pipeline and cash position through acquisitions and strategic sales to strengthen its market leadership.
BioCryst Pharmaceuticals, Inc. (BCRX) Investor Outlook: Exploring a Potential 226.80% Upside
BioCryst Pharmaceuticals (BCRX) presents a compelling investment opportunity with a potential 226.80% upside, driven by its focus on rare disease therapeutics like ORLADEYO and a robust product pipeline. Despite stock volatility and operating in a growth phase without a P/E ratio, the company exhibits strong revenue growth of 36.10% and positive free cash flow. Analysts are overwhelmingly positive, with an average target price of $21.67, underscoring optimism for its future growth and strategic partnerships.
BioCryst to Report Fourth Quarter 2025 Financial Results on February 26
BioCryst Pharmaceuticals, Inc. announced it will report its fourth-quarter 2025 financial results on February 26, 2026. Management will host a conference call and webcast at 8:30 a.m. ET to discuss the results and provide a corporate update. BioCryst focuses on developing and commercializing medicines for rare diseases like hereditary angioedema.
Biocryst expands HAE treatment portfolio with Astria acquisition
BioCryst Pharmaceuticals has acquired Astria Therapeutics, adding navenibart, an investigational treatment for hereditary angioedema (HAE), to its portfolio. Navenibart, an antibody-based therapy, aims to prevent swelling attacks with less frequent dosing and is currently in Phase 3 trials with top-line results expected in 2027. This acquisition, valued at approximately $700 million, expands BioCryst's HAE treatment options alongside their existing drug Orladeyo.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Average Recommendation of "Moderate Buy" from Analysts
BioCryst Pharmaceuticals (NASDAQ:BCRX) has received an average "Moderate Buy" rating from analysts, with ten buy ratings, three holds, and one sell, and an average 1-year price target of $19.50. The company recently missed quarterly EPS and revenue expectations, reporting $0.06 EPS against an estimate of $0.07, and $159.4M in revenue against $162.9M, although revenue increased 36.1% year-over-year. Insider selling activity has been noted, while institutional investors hold approximately 85.9% of the shares.
Royal Bank Of Canada Lowers BioCryst Pharmaceuticals (NASDAQ:BCRX) Price Target to $13.00
Royal Bank of Canada has lowered its price target for BioCryst Pharmaceuticals (NASDAQ:BCRX) to $13.00 from $14.00, while maintaining an "outperform" rating. Other analysts also hold mixed but generally positive views, with a consensus of "Moderate Buy" and an average price target of $19.50. The company recently missed quarterly EPS estimates but saw a 36.1% year-over-year revenue increase, and insiders have been selling shares.
BioCryst Pharmaceuticals Is Quietly Exploding – Is BCRX the Next Sleeper Biotech Rocket or a Total Trap?
BioCryst Pharmaceuticals (BCRX) is gaining attention due to its approved oral therapy for hereditary angioedema (HAE), providing real revenue and a significant market presence. However, it's a high-risk, high-reward investment characterized by biotech volatility and competition from larger pharmaceutical companies. Investors should be prepared for significant price swings and closely monitor sales growth, clinical updates, and funding.
RBC Cuts Price Target on BioCryst Pharmaceuticals to $13 From $14, Keeps Outperform Rating
RBC has lowered its price target for BioCryst Pharmaceuticals (BCRX) to $13 from $14, while maintaining an Outperform rating on the stock. This adjustment comes despite several recent activities for BioCryst, including new board appointments, a loan agreement, and the acquisition of Astria Therapeutics. The company also recently received FDA approval for a pediatric use of its Orladeyo drug and provided positive earnings guidance for Q4 2025 and the full year 2026.
Does Blackstone’s US$400 Million Deal and Astria Hires Change The Bull Case For BioCryst (BCRX)?
BioCryst Pharmaceuticals secured a US$400 million term loan from Blackstone and expanded its leadership with strategic hires from Astria Therapeutics, signaling a significant shift in its financial and operational positioning. This move aims to fund a planned merger, enhance liquidity, and strengthen its rare disease pipeline execution, particularly for ORLADEYO and navenibart. While providing flexibility, the deal also introduces higher-cost debt and balance sheet risk, prompting varied investor perspectives on the company's long-term performance.
Does Blackstone’s US$400 Million Deal and Astria Hires Change The Bull Case For BioCryst (BCRX)?
BioCryst Pharmaceuticals secured a US$400 million term loan from Blackstone and appointed Astria Therapeutics CEO Dr. Jill C. Milne to its Board, along with hiring John Ruesch as Chief Technical Operations Officer. This move provides significant financing for a planned merger and corporate purposes while enhancing expertise in rare disease and development, positioning BioCryst for future growth. However, the deal also adds higher-cost debt, increasing balance sheet risk, and introduces debt service considerations on top of existing challenges for its drug ORLADEYO and pipeline developments.
(BCRX) Risk Channels and Responsive Allocation
This article analyzes Biocryst Pharmaceuticals Inc. (NASDAQ: BCRX), highlighting a strong near-term sentiment that contrasts with persistent mid and long-term weakness. It identifies a mid-channel oscillation pattern and an exceptional 63.5:1 risk-reward short setup targeting 17.5% downside. The analysis also provides AI-generated trading strategies for various risk profiles, including position, momentum breakout, and risk hedging strategies.
A Look At BioCryst Pharmaceuticals (BCRX) Valuation After Mixed Recent Share Price Performance
BioCryst Pharmaceuticals (BCRX) has experienced mixed share price performance recently, with a small gain over one day but declines over the past month, three months, and year. Despite this, the company, with a current share price of US$6.79, is considered significantly undervalued by analysts, who project a fair value of US$20.50, driven largely by the expected growth and expanding market for its drug ORLADEYO. This optimistic valuation hinges on ORLADEYO's continued resilience against competitors and the successful progression of its early-stage pipeline.
BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema
BioCryst Pharmaceuticals has completed its acquisition of Astria Therapeutics, enhancing its leadership in hereditary angioedema (HAE). The acquisition brings navenibart, a late-stage HAE treatment, into BioCryst's portfolio, alongside its existing oral therapy, ORLADEYO. This transaction strengthens BioCryst's position by offering both oral and injectable prophylactic options for HAE patients and includes the addition of two key Astria leaders to BioCryst's board and leadership team.
BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema
BioCryst Pharmaceuticals, Inc. announced the completion of its acquisition of Astria Therapeutics, Inc., a move that strengthens BioCryst's leadership in hereditary angioedema (HAE). This acquisition adds navenibart, a late-stage plasma kallikrein inhibitor with potential for convenient dosing, to BioCryst's HAE portfolio, which already includes ORLADEYO®. The integration aims to leverage BioCryst's existing commercial infrastructure to maximize navenibart's market potential and further enhance individualized patient care options.
A Look At BioCryst Pharmaceuticals (BCRX) Valuation After Mixed Recent Share Price Performance
BioCryst Pharmaceuticals (BCRX) has experienced mixed recent share price performance, with short-term gains but longer-term declines. Despite this, its share price of US$6.79 is significantly below an analyst target of US$20.50, driven by expectations for its drug ORLADEYO and a strong rare disease pipeline. The narrative suggests BioCryst is 66.9% undervalued, contingent on ORLADEYO's continued success against competitors and smooth progress in its early-stage pipeline.
BioCryst Pharmaceuticals Signs Loan Agreement With Blackstone and Lenders
BioCryst Pharmaceuticals has secured a new $400 million, five-year term loan agreement with Blackstone and other lenders. This financing will be used to fund its Astria merger and general corporate needs. The loan carries interest at three-month SOFR plus 4.50%, with an option for PIK interest for two years, and is secured by substantially all of BioCryst's assets.
New HAE shot every 3–6 months? BioCryst’s $700M bet on Astria
BioCryst Pharmaceuticals has completed its acquisition of Astria Therapeutics for approximately $700 million, securing navenibart, a Phase 3 long-acting plasma kallikrein inhibitor for hereditary angioedema (HAE) with potential every-three and every-six-month dosing. This acquisition strengthens BioCryst’s HAE franchise, which already includes the oral therapy ORLADEYO, and is expected to provide individualized treatment options for patients. The deal was financed through cash on hand, a $396.6 million credit facility draw, and the issuance of 37.3 million shares to Astria equity holders.
BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema
BioCryst Pharmaceuticals has completed its acquisition of Astria Therapeutics, strengthening its position in hereditary angioedema (HAE) treatment. This acquisition adds navenibart, a late-stage plasma kallikrein inhibitor with potential for convenient dosing, to BioCryst's HAE portfolio, complementing their oral therapy ORLADEYO®. The integration aims to enhance individualized patient care and leverage BioCryst's existing commercial infrastructure.
Astria stockholders approve acquisition by BioCryst
Astria Therapeutics stockholders have approved the company's acquisition by BioCryst Pharmaceuticals. The merger is anticipated to close around January 23, 2026, pending customary conditions. Astria, a biopharmaceutical company focused on allergic and immunologic diseases, has demonstrated significant stock momentum and positive clinical trial outcomes for its lead hereditary angioedema treatment.
Astria Stockholders Vote to Approve Acquisition by BioCryst
Astria Therapeutics, Inc. (Nasdaq: ATXS) announced that its stockholders approved the acquisition by BioCryst Pharmaceuticals, Inc. at a special meeting held on January 21, 2026. The merger is anticipated to close around January 23, 2026, subject to customary closing conditions. Astria focuses on developing therapies for allergic and immunologic diseases, with lead programs navenibart for hereditary angioedema and STAR-0310 for atopic dermatitis.
Campbell & CO Investment Adviser LLC Decreases Position in BioCryst Pharmaceuticals, Inc. $BCRX
Campbell & CO Investment Adviser LLC significantly reduced its stake in BioCryst Pharmaceuticals (NASDAQ:BCRX) by 73.4% in Q3, selling over 300,000 shares. Despite this, other institutions aggressively increased their positions, leading to institutional investors owning 85.88% of the company. BioCryst's shares were down 7.1% at $6.66, and while Q3 revenue increased by 36.1%, EPS missed estimates, and the company remains unprofitable.
Does BioCryst (BCRX) 2026 Revenue Guidance Reframe the ORLADEYO Growth Story for Investors?
BioCryst Pharmaceuticals recently issued 2026 revenue guidance of US$635 million to US$660 million, following its presentation at the J.P. Morgan Healthcare Conference. This guidance, coupled with a raised 2025 outlook, provides a clearer benchmark for the company's ORLADEYO-led growth trajectory and its exposure to a single therapy amidst increasing competition. However, while the new targets indicate higher revenue, they also highlight a concentration risk that investors should consider.
A Look At BioCryst Pharmaceuticals (BCRX) Valuation After Its New 2026 Revenue Guidance
BioCryst Pharmaceuticals (BCRX) provided 2026 revenue guidance of US$635 million to US$660 million, yet its recent stock performance has been weak. Despite the weak trading, Simply Wall St's analysis suggests the stock is currently undervalued at $6.66 compared to a fair value of $20.60, primarily driven by expectations of strong revenue growth for ORLADEYO and expansion into new indications. The valuation, however, depends on ORLADEYO's performance in a competitive market and the success of early-stage pipeline programs.
A Look At BioCryst Pharmaceuticals (BCRX) Valuation After Its New 2026 Revenue Guidance
BioCryst Pharmaceuticals (BCRX) recently released its 2026 revenue guidance, projecting US$635 million to US$660 million, following weak recent trading performance. Despite this, a common narrative suggests the stock is significantly undervalued, with a fair value of US$20.60 against its current price of US$6.66, based on strong expected growth in rare disease revenues, particularly from ORLADEYO. This optimistic valuation, however, depends on ORLADEYO maintaining market share and early pipeline programs succeeding.
